Theresa Mai-Hwang
Physician Assistant · Stanford, CANPI 1629670914
Payments from drug & device makers
Across 375 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Xeris Pharmaceuticals, Inc.$979
- IBSA Pharma Inc.$564
- Corcept Therapeutics$506
- Bayer$471
- plus $4K from 34 others
What the payments were for
- Food & beverage$9,245100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,266 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 645 | $653,312 |
| OzempicSemaglutide | 462 | $649,040 |
| RybelsusSemaglutide | 188 | $279,898 |
| TrulicityDulaglutide | 185 | $232,985 |
| FarxigaDapagliflozin Propanediol | 159 | $175,858 |
| MounjaroTirzepatide | 64 | $84,284 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 48 | $63,407 |
| Tresiba Flextouch U-100Insulin Degludec | 107 | $59,051 |
| InvokanaCanagliflozin | 64 | $54,909 |
| JanuviaSitagliptin Phosphate | 55 | $54,291 |
| TradjentaLinagliptin | 47 | $46,829 |
| Humalog Kwikpen U-100Insulin Lispro | 118 | $37,127 |
| KerendiaFinerenone | 36 | $36,770 |
| Teriparatide | 12 | $24,661 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $23,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,378 | $928,938650 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr | $32 | $734,183727 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,426 | $317,269249 claims |
| AstraZenecaFarxiga | $219 | $175,858159 claims |
| MerckJanuvia | $38 | $54,29155 claims |
| BayerKerendia | $471 | $36,77036 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Stanford
- Andrea FoxStanford$172K
- Traci HornbeckStanford$48K
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.